Time in

Vilnius, Tallinn, Riga

www.worldpharmanews.com

Syndicate content World Pharma News
World Pharma News - one of the world's leading web-based pharmaceutical news publications - is committed to providing and disseminating the most prominent pharmaceutical news and achievements
Updated: 14 weeks 2 days ago

Personalized cancer vaccine may increase long-term survival in patients with deadly brain cancer

Mon, 06/04/2018 - 10:00
An international Phase III study led by researchers at UCLA and at Northwest Biotherapeutics, Inc. has found that a personalized glioblastoma vaccine may increase long-term survival in some patients. Nearly 30 percent of patients in the current trial have now survived at least three years post-enrollment, with patients continuing to be followed over time.
Categories: Category 2

Ophthalmic Drugs Conference 2018

Fri, 06/01/2018 - 14:54
26 - 27 November 2018, London, UK.
As the global population ages, the incidence of ophthalmic disorders continues to grow, and thus the interest of pharmaceutical and biotech companies is increasingly focused towards innovation of novel approaches for the development of ophthalmic drugs, driving the growth of the global ophthalmic drug market, which is projected to reach £30 billion by 2023.
Categories: Category 2

New findings link estrogen and T cell immune response to autoimmune inflammation

Thu, 05/31/2018 - 12:00
Women are more prone to the development of autoimmune diseases. The female hormone estrogen is likely to affect the immune system. A team of scientists from Turku Center for Biotechnology and University of Georgia reported new findings related to the involvement of estrogen hormone receptor in autoimmune diseases.
Categories: Category 2

The Pfizer Foundation announces $5 million in grants to support women and families

Thu, 05/31/2018 - 10:00
The Pfizer Foundation announced a new $5 million grant commitment to initiatives in low- and middle-income countries that provide family planning access and education for women and men at the same time children are routinely vaccinated. These new grants build on The Pfizer Foundation's existing grant program by providing a second round of funding to international nongovernmental organizations (INGOs) in five African countries where different barriers exist for women to access family planning services, bringing the total program funding to $11.7 million to date.
Categories: Category 2

Soy lecithin NSAID combo drug protects against cancer with fewer side effects

Wed, 05/30/2018 - 12:00
When scientists at The University of Texas Health Science Center at Houston (UTHealth) applied a chemical found in soybeans to a non-steroidal anti-inflammatory drug (NSAID), they increased its anticancer properties and reduced its side effects. Findings of the preclinical study of phosphatidylcholine, also called lecithin, appear in the journal Oncology Letters.
Categories: Category 2

Amgen Foundation and Harvard team up to offer free online science education platform

Wed, 05/30/2018 - 10:00
The Amgen Foundation and Harvard University today announced plans to launch a free online science education platform uniquely designed to level the playing field for aspiring scientists. The LabXchange platform, which will launch with a focus in biology, will offer digital instruction and virtual lab experiences to high school and college students, enabling them to gain meaningful exposure to the scientific process.
Categories: Category 2

New drugs could also be deployed against lung and pancreatic cancers

Tue, 05/29/2018 - 12:00
A new anti-cancer drug may be effective against a wider range of cancers than previously thought. Using a mouse model and samples taken from cancer patients, a team from the Technical University of Munich (TUM) has shown that a new class of drugs known as SHP2 inhibitors is also effective against aggressive, hard-to-treat tumors such as lung and pancreatic cancers. Clinical trials currently underway had previously excluded patients with these cancers.
Categories: Category 2

FDA takes new steps to advance digital health, opening docket to solicit feedback on software products

Tue, 05/29/2018 - 10:00
Today, the FDA is opening a docket to solicit feedback on important provisions of the 21st Century Cures Act ("Cures Act"). The Cures Act amended the Federal Food, Drug, and Cosmetic Act to exclude certain medical software functions from the definition of a medical device. Under the Cures Act, Congress excluded specific types of software from FDA regulation, including general wellness software products, electronic patient records and more.
Categories: Category 2

Most popular vitamin and mineral supplements provide no health benefit, study finds

Mon, 05/28/2018 - 12:00
The most commonly consumed vitamin and mineral supplements provide no consistent health benefit or harm, suggests a new study led by researchers at St. Michael's Hospital and the University of Toronto. Published today in the Journal of the American College of Cardiology, the systematic review of existing data and single randomized control trials published in English from January 2012 to October 2017 found that multivitamins, vitamin D, calcium and vitamin C
Categories: Category 2

Patient-reported outcomes tool revealed significant improvement in symptom frequency and quality of life domains with Entresto®

Mon, 05/28/2018 - 10:00
Novartis announced today new real world evidence from the CHAMP-HF registry comparing Entresto® (sacubitril/valsartan) patients to patients not taking Entresto.[1] This pre-specified analysis of an interim data cut from the CHAMP-HF registry showed that chronic heart failure (HF) patients with reduced ejection fraction (HFrEF) taking Entresto reported early, statistically significant improvement in health status, as measured by the KCCQ-12 overall summary score (KCCQ-OS).
Categories: Category 2

Tiny particles could help fight brain cancer

Fri, 05/25/2018 - 10:00
Glioblastoma multiforme, a type of brain tumor, is one of the most difficult-to-treat cancers. Only a handful of drugs are approved to treat glioblastoma, and the median life expectancy for patients diagnosed with the disease is less than 15 months. MIT researchers have now devised a new drug-delivering nanoparticle that could offer a better way to treat glioblastoma. The particles, which carry two different drugs, are designed so that they can easily cross the blood-brain barrier and bind directly to tumor cells.
Categories: Category 2

AstraZeneca heads to 2018 ASCO Annual Meeting with its diversified oncology portfolio and next-generation pipeline

Thu, 05/24/2018 - 12:00
AstraZeneca and MedImmune, its global biologics research and development arm, head to the 2018 American Society of Clinical Oncology (ASCO) Annual Meeting in Chicago, US, 1-5 June 2018, with an expanded portfolio in Oncology. Having achieved 16 regulatory approvals across major markets (US, EU, Japan and China), AstraZeneca will be sharing its R&D momentum at ASCO with seven "Best of ASCO" presentations and 14 oral presentations from a total of 91 accepted abstracts.
Categories: Category 2

Study finds antioxidant-enriched vitamin reduces respiratory illnesses in patients with CF

Thu, 05/24/2018 - 10:00
Researchers at Children's Hospital Colorado (Children's Colorado) and the University of Colorado School of Medicine have found that taking a specially formulated antioxidant-enriched multivitamin may decrease respiratory illnesses in people with cystic fibrosis (CF). The study, which was recently published online in the American Journal of Respiratory and Critical Care Medicine, looked at the effects of a 'cocktail' of multiple antioxidants on inflammation and health outcomes in patients with CF.
Categories: Category 2

Spiolto® Respimat® enables greater physical activity in people living with Chronic Obstructive Pulmonary Disease

Wed, 05/23/2018 - 12:00
Boehringer Ingelheim announced data which add to the growing body of evidence that show Spiolto® (tiotropium/olodaterol) Respimat® enables greater physical activity in patients living with COPD. VESUTO® and OTIVATO® data were presented during the American Thoracic Society meeting (ATS) and PHYSACTO® data was recently published in the American Journal of Respiratory and Critical Care Medicine.
Categories: Category 2

Antidepressant use may contribute to long-term population weight gain

Wed, 05/23/2018 - 10:00
Researchers at King's College London have found that patients prescribed any of the 12 most commonly used antidepressants were 21% more likely to experience an episode of gain weight than those not taking the drugs, (after adjusting for other factors which might affect this result). The full research is published in the BMJ.
Categories: Category 2

Pfizer begins a Phase 1/2 study to evaluate respiratory syncytial virus (RSV) vaccine

Tue, 05/22/2018 - 12:00
Pfizer Inc. (NYSE:PFE) today announced that it has started a Phase 1/2 trial of its respiratory syncytial virus (RSV) vaccine candidate in healthy adult volunteers. RSV is a common respiratory virus that affects the lungs and airways, with significant impact on young children and older adults. RSV affects 33 million children globally and leads to approximately 120,000 childhood deaths every year.
Categories: Category 2

Study demonstrates new treatment for severe asthma

Tue, 05/22/2018 - 10:00
Researchers from McMaster University and the Firestone Institute for Respiratory Health at St. Joseph's Healthcare Hamilton, together with colleagues at other partnering institutions, have developed a new method to treat severe asthma. In a study of over 200 participants with severe asthma, the new treatment was shown to have improved asthma symptoms and lung function, while reducing the need for corticosteroids by up to 70%.
Categories: Category 2

Eczema drug effective against severe asthma

Mon, 05/21/2018 - 12:00
Two new studies of patients with difficult-to-control asthma show that the eczema drug dupilumab alleviates asthma symptoms and improves patients' ability to breathe better than standard therapies. Dupilumab, an injectable anti-inflammatory drug, was approved in 2017 by the Food and Drug Administration as a treatment for eczema, a chronic skin disease.
Categories: Category 2

Novartis data at ASCO and EHA reinforce company's commitment to reimagining cancer

Mon, 05/21/2018 - 10:00
Novartis will present data from across its oncology portfolio at the upcoming 54th Annual Meeting of the American Society of Clinical Oncology (ASCO) to be held June 1-5 in Chicago; and the 23rd Annual Congress of the European Hematology Association (EHA), scheduled for June 14-17 in Stockholm.
Categories: Category 2

Ovarian cancer drug shows promise in pancreatic cancer patients with BRCA mutation

Fri, 05/18/2018 - 12:00
A targeted therapy that has shown its power in fighting ovarian cancer in women including those with BRCA1 and BRCA2 mutations may also help patients with aggressive pancreatic cancer who harbor these mutations and have few or no other treatment options. An international team of researchers led by the Perelman School of Medicine and the Basser Center for BRCA at the University of Pennsylvania reported their findings this week in JCO Precision Oncology.
Categories: Category 2
  • Professionalism.
    We are specialists in this field and like our activity, so we can guarantee the quality of our work.
  • Competitiveness.
    Individual solutions for a competitive price.
  • Confidentiality.
    We appreciate the cooperation, maintain confidentiality and seek for a long-term partnership

Member of Medicines Manufacturers Association